Inclusion Criteria:

1. 18 - 75 yrs
2. Available for clinical follow-up for study duration
3. Able/willing to give written consent
4. Good general health; no clinically significant medical history
5. Adequate venous access
6. PE and lab results without clinically significant findings <14d from 1st study drug dose
7. Body mass index <35
8. Able and willing to avoid alcohol for screening and study duration
9. Negative beta-hCG pregnancy test (urine or serum) at screening and Day 1.
10. Participant or partner has undergone surgical sterilization, or participant has been post-menopausal for >1 year, is heterosexually inactive (abstinent), or uses contraception (screening - 3 months after last study drug dose): Condoms (male or female), diaphragm/cervical cap, or intrauerine device, all with spermicide, or oral contraceptives or other hormonal methods

Exclusion Criteria:

1. Pregnant, breast-feeding, or planning to become pregnant <3 mths after last study drug dose

2. History of clinically significant conditions including:

   • Asthma treated with systemic steroids in last 6 mths
   • Serious angioedema in last 3 yrs, or needing medication in last 2 yrs
   • Hypertension with repeated >140 systolic and/or >90 diastolic
   • Head trauma and diagnosis of traumatic brain injury other than concussion
   • Family history of idiopathic seizures
3. Activity limitations due to cardiac disease
4. Diagnosed bleeding disorder, e.g., factor deficiency, coagulopathy, or platelet disorder, or severe bruising/bleeding with IM injections or blood draws
5. Current use of insulin, anti-convulsive, or anti-coagulation therapy
6. Active malignancy, or malignancy treatment with no assurance of sustained cure, or recurrence likely during study period
7. History of seizure
8. Clinically significant blood dyscrasia
9. History of drug allergy that contraindicates study participation
10. Medical, psychiatric, social, occupational or other reason that jeopardizes the safety/rights of participant or renders he/she unable to comply with the protocol (including homelessness)
11. Inability to swallow study medication
12. Clinically abnormal ECG
13. QTcF (Fridericia's correction) >450 msec
14. Has or will participate in a clinical trial or experimental treatment within 30 days of, or during, the study
15. Drug or alcohol abuse within the last year. Drug screening for ethanol, amphetamines/methamphetamines, cannabinoids, opiates, cocaine and barbiturates
16. Must do physical exercise 24 hrs before and after PK days
17. Must consume grapefruit/grapefruit juice during study
18. Vaccination within 2 wks of screening, or planned before Day 42 of study
19. Total >350mL blood (not plasma) drawn <2 mths before given study drug or after study completion
20. Current clinical bacterial, fungal, mycobacterial or viral infection
21. Known Hepatitis B or C infection or positive test at screening (determination of HBsAg, HBcAb, and HCVAb)
22. Known HIV infection or AIDS, or positive test regardless of CD4 count for HIV at screening
23. Chronic viral infection, e.g., human T-cell lymphotropic Virus I or II
24. Chronic bacterial, mycobacterial, fungal, parasitic or protozoal infection, except clinically insignificant dermal infections
25. Treatment with >20 mg prednisone or equivalent immunosuppressant/modulatory drug dose <3 mths before screening

26. Lab results <14 days prior to first study drug dose, as follows:

    • Serum creatinine clearance (Cockcroft-Gault) <30 mL/min
    • Creatinine in males >1.7 and females >1.4 (1.3X upper limit of normal central lab range (ULN))
    • Hemoglobin < or = 10% below ULN, or higher
    • WBC not within CL normal range
    • Absolute neutrophil count <1,000/mm3
    • Platelets not within 10% of normal CL range
    • Alanine aminotransferase >2X ULN
    • Aspartate aminotransferase >2X ULN
    • Alkaline phosphatase >10% above ULN
    • Hemoglobin A1c > or = 7.0 (includes diabetics on controlled diets or oral hypoglycemics)